NorthSea Therapeutics

Description

NorthSea Therapeutics B.V. is a private, late-stage clinical biotechnology company that leverages its structurally engineered fatty acids (SEFAs) platform to develop novel drugs that target cholestatic, inflammatory, and fibrotic pathways to treat heterogeneous rare liver diseases that require a multi-modal mechanism of action (MOA). Its proprietary structurally engineered fatty acids (SEFAs) are designed to target key disease pathways, offering potential first-in-class treatments. NorthSea’s lead program is orziloben, a Phase 2 program for the treatment of intestinal failure-associated liver disease (IFALD). NorthSea’s investors include Forbion, Ysios Capital, venBio, Novo Seeds, Sofinnova, BGV, and New Science Ventures. Headquartered in the Netherlands, NorthSea also has a presence in the U.S. and Norway.